



Available online on 15.09.2017 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited



Open  Access

Review Article

FLIBANSERIN: A HAPPY ENDING SOLUTION TO HYPOACTIVE SEXUAL DESIRE DISORDER

Dick B. S. Brashier¹, Prashant Mishra^{2*}, Neha Akhoo³, Htet Wai Moe³, Kedar G. Bandekar³

¹Professor, Department of Pharmacology, Armed Forces Medical College, Pune– 411 040, Maharashtra, India

²Classified Specialist (Pharmacology), Armed Forces Medical Services, New Delhi – 110001, India

³Resident, Department of Pharmacology, Armed Forces Medical College, Pune– 411 040, Maharashtra, India

ABSTRACT

Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexual desire. It can cause prominent distress and interpersonal difficulty of women. There have been drugs available to treat sexual disorders in men when there is no such drug for women. Nowadays, FDA approved Flibanserin to treat HSDD of premenopausal women. This drug Flibanserin has no novel mechanism of action but the possible mechanism of action is modulating serotonin and dopamine activity in brain parts as balance of these systems is significance for a normal sexual response.

Keywords: Hypoactive Sexual Desire Disorder, Premenopausal women, Flibanserin

Article Info: Received 25 July, 2017; Review Completed 09 August, 2017; Accepted 09 August, 2017; Available online 15 Sep, 2017



Cite this article as:

Brashier DBS, Mishra P, Akhoo N, Moe HW, Bandekar KG, Flibanserin: A happy ending solution to hypoactive sexual desire disorder, Journal of Drug Delivery and Therapeutics. 2017; 7(5):1-3

DOI: <http://dx.doi.org/10.22270/jddt.v7i5.1504>

*Address for Correspondence

Prashant Mishra, Classified Specialist (Pharmacology), Armed Forces Medical Services, New Delhi – 110001, INDIA. Email: drpmfmc@gmail.com

INTRODUCTION

In today era, where women are at par with men in every sphere of life, distress be it in relation to their professional life or personal life, it does prevail. Hypoactive sexual desire disorder (HSDD) which is characterized by persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity is one such disorder which may arise due to personal distress¹. This entity HSDD includes two further disorders, Female sexual arousal disorder (FSAD) and Female sexual interest arousal disorder (FSIAD) (FDA briefing document). In 2006, the women's international study of Health and sexuality (WISH) assessed the prevalence of HSDD and found out 24-36% of women between 20 and 70 year of age had problems with low sexual desire². Now the question which remains unanswered is, since there has been a line of drug coming upto treat such disorders in males, why much

research work has not been found to treat the same problem in women. Complex physiology of female genital tract might come up as an answer, but does not suffice³.

Finally a wonder drug with no novel mechanism of action, called Flibanserin has come up and has been approved by FDA in August 2015⁴.

MECHANISM OF ACTION

Flibanserin binds to 5 hydroxytryptamine (5HT_{1A}) receptor and acts as an agonist and it also acts as 5HT_{2A} receptor antagonist. It also has weak partial agonist activity at Dopamine (D₄) receptor. The proposed mechanism of action refers to Kinsey dual control model of sexual response⁵. Various NT sex steroids are other hormones that have excitatory inhibitory on sexual response. Amongst NT, excitatory activity is driven by dopamine and noradrenaline while inhibitory activity is

driven by serotonin⁶. The balance of these systems is significance for a normal sexual response. By modulating serotonin and dopamine activity in brain parts, Flibanserin improves the balance in regulation of sexual response⁷.

PHARMACOKINETICS

Flibanserin is rapidly absorbed with 90% of dose reaching systemic circulation as drug itself or its metabolite. After oral administration, maximum plasma concentration (C_{max}) is usually achieved in 45-60 minutes. Absolute bioavailability following oral dosing is 33%. Food moderately affects the rate and extent of its absorption⁸.

It is metabolized by CYP3A4 and to minor extent by CYP2D6. It is excreted as conjugated metabolite via bile and kidney. Terminal $t_{1/2}$ is approximately 12 hours⁹.

DRUG INTERACTIONS

Strong CYP3A4 and CYP2D6 inhibitors and inducers can alter the level of Flibanserin. Concomitant administration with alcohol increases the risk of somnolence, fatigue, orthostatic hypotension and syncope. Interaction with CYP3A4 inhibitor like fluconazole increases the risk of syncope and symptomatic hypotension¹⁰.

ADVERSE DRUG REACTIONS

Most common reported adverse events included dizziness, nausea, and tiredness, disturbance in sleep. Concomitant intake of alcohol with Flibanserin results in severely low blood pressure¹¹.

CLINICAL TRIALS

The drug has faced many issues in the past regarding its approval. In 2010, approval was denied pertaining to inadequate risk-benefit ratio. In June 2015, USFDA advisory committee recommended approval of the drug¹². In August 2015, FDA finally approved Flibanserin for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties. It was specially specified that it should not be used to treat low sexual desire caused by coexisting psychiatric or medical reasons. There are four main randomized controlled trials done to get approval of FDA¹³.

DAISY STUDY

Premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) were randomized and treated with doses of Flibanserin 25mg and 50mg twice daily and 100mg once daily at night time or placebo for 24 weeks. The mean age of women is 35 years. Results showed that women receiving Flibanserin 50mg twice daily and 100mg once daily considered that their HSDD had

improved with treatment (44% and 47% respectively). Only 30% of women receiving placebo receivers consider improvement. It can be found that in premenopausal women suffering from HSDD, Flibanserin 100mg once daily was tolerated and showed statistically significant improvement in sexual desire, sexual function and decrease of sexual distress compared to placebo¹⁴.

VIOLET STUDY

Premenopausal women with HSDD were randomized and treated with Flibanserin 50mg, Flibanserin 100mg or placebo once daily dose at night time for 24 weeks. About 39% and 50% of women respectively receiving 50mg and 100mg Flibanserin considered improvement when only 30% of women receiving placebo considered improvement¹⁵.

BEGONIA STUDY

Premenopausal women (mean age: 36.6 years) were randomized and given treatment with Flibanserin 100mg once daily dose at night time or placebo for duration of 24 weeks. The 38% of women treated with Flibanserin considered marked improvement and also showed significant reductions in distress associated with sexual dysfunction. Only 28% of placebo group considered improvement¹⁶.

SNOWDROP STUDY

Postmenopausal women with HSDD were treated with Flibanserin 100mg once daily at night time or placebo for 24 weeks. The 37% of women treated with Flibanserin 100mg and 28% of women receiving placebo considered the improvement respectively¹⁷.

DRUG ABUSE AND DEPENDENCE

There is no increase in drug-seeking behavior, misuse and abuse once marketed. The only possible abuse is that men can force their partner to take this medicine to increase their desire¹⁸.

PRESENT STATUS

Flibanserin is available as 100 mg tablet. The recommended dose is 100 mg taken one time a day at bedtime. It can be taken only at bedtime as it can increase the risk of low blood pressure, fainting attack, accidental injury and sleepiness¹⁹.

CONCLUSION

Hypoactive Sexual Desire Disorder (HSDD) is a woman's ongoing lack of sexual interest or desire that causes prominent distress and interpersonal difficulty. Flibanserin is the first and only approved drug of FDA to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women²⁰.

REFERENCES

1. Clayton AH, Goldfischer E, Goldstein I, DeRogatis L, Nappi R, Lewis-D'Agostino DJ, Kimura T, Hebert A, Pyke R. Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder. *J Sex Marital Ther* 2013; 39:132–43.
2. Clayton AH, DeRogatis LR, Rosen RC, Pyke R. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. For women with incomplete loss of desire or sexual receptivity. *J Sex Med* 2012; 9:2027–39.
3. Basson R, Driscoll M, Correia S. Flibanserin for Low Sexual Desire in Women: A Molecule from Bench to Bed? *EBioMedicine*. 2015; 2(8):772-773.
4. Gohil K. Pharmaceutical Approval Update. *Pharmacy and Therapeutics*. 2015; 40(10):649-689.
5. Uphouse L. Pharmacology of serotonin and female sexual behavior. *Pharmacology, biochemistry, and behavior*. 2014; 0:31-42.
6. Zakiniaez Y, Cosgrove KP, Potenza MN, Mazure CM. Balance of the Sexes: Addressing Sex Differences in Preclinical Research. *The Yale Journal of Biology and Medicine*. 2016; 89(2):255-259.
7. Chilmonec Z, Bojarski AJ, Pilc A, Sylte I. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Hashimoto K, ed. *International Journal of Molecular Sciences*. 2015; 16(8):18474-18506.
8. Sang JH, Kim T-H, Kim SA. Flibanserin for Treating Hypoactive Sexual Desire Disorder. *Journal of Menopausal Medicine*. 2016; 22(1):9-13.
9. Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. *CNS Spectr* 2015; 20:1–6.
10. Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? *Expert Opin Pharmacother* 2015; 16:1735–8.
11. Levine SB. Flibanserin. *BMJ* 2015; 350:h3097.
12. Uphouse L. Pharmacology of serotonin and female sexual behavior. *Pharmacology, biochemistry, and behavior*. 2014; 0:31-42.
13. Zhenli Gao, Diandong Yang, Luxin Yu, MD, Yuanshan Cui. Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis. *J Sex Med* 2015; 12:2095–2104.
14. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia MJ, Lesko L, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. *J Sex Med* 2012; 9:793–804.
15. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia MJ, Wunderlich G, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET Study. *J Sex Med* 2012; 9:1074–85.
16. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia MJ, Sand M. Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. *J Sex Med* 2013; 10:1807–15.
17. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia MJ, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial. *Menopause* 2014; 21:633–40.
18. Gohil K. Pharmaceutical Approval Update. *Pharmacy and Therapeutics*. 015; 40(10):649-689.
19. Addyi Approval History. Available at: <https://www.drugs.com/history/addyi.html> Accessed on 18.08.2016.
20. FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder. Available at: <http://www.nejm.org/doi/full/10.1056/NEJMp1513686#t=article> Accessed on 18.08.2016.

